Background. We compared the efficacy and safety of different dosages of a low-molecular-weight heparin, CY 216 D (Fraxiparine), in the treatment of submassive pulmonary embolism with unfractionated heparin in a prospective, randomized, dose-finding study.
U Tnfractionated heparin (UFH) is generally accepted as the front-line treatment for most patients with minor and submassive pulmonary embolism (PE).1-3 It is associated with a significant risk of bleeding,4 however, and its recommended mode of administration requires admission to hospital for continuous intravenous infusion and frequent laboratory controls for dose adjustment.5 In laboratory-tested animals, low-molecular-weight heparins (LMWHs) can prevent formation or extension of an experimental thrombus as effectively as UFH with a lower risk of bleeding. 6 Several clinical randomized studies on a large number of patients have shown that LMWHs are effective and safe in preventing postoperative venous thromboembolism both in general surgery7-10 and in high-risk orthopedic surgery.11'2 Preliminary studies in the curative treatment of deep vein thrombosis (DVT) showed *pulmonary embolism * thrombosis * clinical that LMWHs were as effective and safe as UFH. [13] [14] [15] A recent large randomized trial on the treatment of DVT showed that a LMWH (Fraxiparine®) administered subcutaneously at a fixed daily dose of 450 anti-Xa Institute Choay units/kg (AXa IC U/kg), without any laboratory control adjustments, yielded a better phlebographic improvement than continuous intravenous UFH without increasing the risk of bleeding or the embolic recurrence rate. 16 This study represents the first controlled randomized trial conducted with a LMWH (Fraxiparine) in the curative treatment of submassive PE. In this trial, three therapeutic dosages of the LMWH were tested versus UFH to determine the optimal dose (benefit/ risk ratio): a dosage of 400 AXa IC U/kg per day, lower than the 450 AXa IC U/kg previously used in the curative DVT trial, and two larger dosages (600 and 900 AXa IC U/kg per day).
Methods
This was a dose-finding controlled, randomized, prospective, collaborative study comparing three fixed dosages of Fraxiparine administered subcutaneously with a daily adjusted intravenous continuous infusion of UFH. The study could not be performed double-blind because of the different modes of administration and above all the need for dosage adjustments in the UFH group. However, the main assessment criterion (pulmonary angiography) was blindly evaluated by a central independent panel of three radiologists (coded films). The study protocol was approved by the ethics committee of the Hopital Cardiologique, Lille, France. Patients entering the study gave informed consent. Primary end point was the angiographic evolution of pulmonary vascular obstruction assessed before inclusion (day 0) and after 8 days (day 8+1) of treatment. Secondary end points were the venographic evolution of the eventual associated DVT, clinical recurrences of thromboembolic events, and bleedings during the treatment (day 14+ 1).
Between October 1986 and December 1988, a total of 101 patients were enrolled by 14 centers. All patients aged 18 years or more with a recent angiographically proved PE (within 3 days of the onset of symptoms) and with a pulmonary vascular obstruction assessed by the local radiologists between 15% and 55% (index of severity according to Miller 5 to 18)17 were eligible for the study. Exclusion criteria were angiographically determined vascular obstruction <15% or >55% as assessed by local radiologists; any sign of clinical severity defined as shock, acute cor pulmonale, or right heart failure; any contraindication to heparin: active peptic ulcer, recent history of cerebrovascular hemorrhage or ischemia, known bleeding tendency, previous history of heparin-induced thrombocytopenia, hemorrhagic diathesis, preexisting coagulation disorders, severe renal or hepatic dysfunction, severe systemic hypertension, known pericarditis or endocarditis, pregnancy, preexisting DVT or PE within 12 months preceding the inclusion, or use of thrombolytic agents (urokinase or streptokinase); heparin at therapeutic doses >20,000 IU per day for more than 48 hours before inclusion; oral anticoagulants; acetylsalicylic acid or ticlopidine during the 7 days before inclusion; platelet count <100,000/ mm3; any contraindication to isotopic or angiographic investigations; and free-floating inferior vena cava thrombus.
Fraxiparine (Sanofi Choay, France) is the calcium salt of the LMWH obtained from porcine mucosal heparin (specific activity s45 anti-Ila IU/mg and .180 AXa IC U/mg determined with the fourth International UFH Standard as a control, with a mean molecular weight of 4,500 d; range, 1,800-8,000 d). It was supplied in 0.6-ml vials containing 15,000-25,000 AXa IC U/ml (1 AXa IC U equals -0.4 IU for LMWH).H8 UFH (Sanofi Choay, France) is a porcine mucosal sodium salt heparin (specific activity >170 IU/mg) supplied in 5-ml vials each containing 25,000 IU (5,000 IU/ml).
After local angiographic assessment (day 0), patients were randomly allocated to 14 days of treatment with UFH or LMWH. Randomized treatment allocation schedules were prepared for each clinical center using sealed treatment allocation envelopes. The patients were distributed in four groups (one UFH group and three LMWH groups); in the UFH group (group 1), each patient received an intravenous bolus injection of 50 IU/kg followed by continuous infusion of an initial dose of 600 IU/kg. The dosage was then adjusted so as to keep the activated partial thromboplastin time (aPIT) between 2.5 and 3 times the control. In the LMWH groups, the patients received Fraxiparine ad-ministered subcutaneously at a fixed daily dosage of 400 AXa IC U/kg (group 2) divided into two daily injections, 600 AXa IC U/kg (group 3) into three injections, and 900 AXa IC U/kg (group 4) into three injections. After day 14±1, each center continued its own anticoagulant therapy (UFH or oral anticoagulant). During the trial period, PE recurrences, adverse events, or major bleedings were monitored in the four groups by a steering committee so as to stop inclusion in any of the three LMWH groups if its event rate increased by more than 50% compared with the UFH group. Pulmonary angiography was performed at day 0 and day 8±1 after the onset of treatment with a conventional or digitalized technique by selective injection into the main pulmonary artery. Bilateral venography of the lower limbs, including vena cava investigation (ascending contrast venography), was also performed at day 0 in all patients and at day 8. The method used in this study has been described previously'9: it was performed by bolus injection of contrast medium in a dorsal vein of each foot, which allowed analysis of the deep vein system only. A Valsalva maneuver with the elevation of both legs was systematically performed before the last film was taken to obtain better visualization of the iliac vein and vena cava. Cavography was performed when the visualization of these veins was judged insufficient on phlebograms or as complementary investigation after pulmonary angiography. This allowed a correct visualization of the vena cava in 91 patients.
Pulmonary angiograms and venograms were subsequently reviewed by a central independent panel of three radiologists unaware of the treatment allocation and of the chronology of the angiograms and venograms. A consensus score was then established if necessary. Discrepancies between radiological readers occurred in five angiographies (2.5%), requiring new readings from the third radiologists to reach a consensus.
The degree of the pulmonary arterial occlusion was assessed by the severity score system proposed by Miller.17 Briefly, the angiographic score of severity takes into account the presence of filling defects in the pulmonary artery and its branches (maximum, 16) and the impairment of the pulmonary artery flow (maximum, 18). A filling defect in a segmental artery scored one point, but when it involved a more proximal branch (lobar or main pulmonary artery), it scored a value equal to the number of segmental branches arising distally. Thus, the maximal score for filling defects was nine for the right pulmonary artery (regarded as having nine segmental branches) and seven for the left. The perfusion was scored as follows: each lung was divided into three zones; in each of them, the flow was assessed as absent (three points), severely reduced (two points), mildly reduced (one point), or normal (no point). The maximum perfusion score was therefore nine points for each lung, leading to a maximum score of severity of 34 points.
A quantitative assessment of DVT was made according to Arnesen's scoring. 20 The following score point system was devised for each vein examined (anterior and posterior tibial veins, peroneal veins, popliteal vein, and iliofemoral vein): 0, vein not involved by the thrombus; 1, involvement up to one third of the vein without occlusion; 2, involvement up to two thirds of the vein without occlusion or involvement up to one third of the vein with occlusion; 3, involvement up to three thirds of the vein without occlusion or involvement up to two thirds of the vein with occlusion; 4, involvement up to three thirds of the vein with occlusion; 5, no visualization of the vein because of complete occlusion.
Follow-up of the patients consisted of a daily physical examination by the investigators. The following data were recorded: evolution or recurrences of PE, signs of DVT and bleedings, or other adverse events. In case of suspected recurrent embolism, the diagnosis required the appearance of intraluminal filling defect or sharp arterial cutoff in an area not previously involved in the embolic process and/or more proximal extension of vascular obstruction compared with the reference angiography. The disappearance of a proximal clot with embolization of more distal arteries in the same area without any other changes was interpreted as fragmentation of the initial clot and was not considered a recurrence. '9 Hemorrhagic tolerance was assessed on the rate of major and minor bleeding events. Bleeding events that did not lead to treatment cessation, such as hematomas at injection sites, microscopic hematurias, gingivorrhagias, and minor epistaxis, were considered "minor."' Bleeding was classified as "major" if it required treatment cessation, transfusion, or surgery, such as retroperitoneal or intracranial hemorrhage, gastrointestinal bleeding with hematemesis or melena, or hemarthrosis of a big joint.
Blood samples were collected for hemostasis investigation at day 0 and then once daily in test tubes with 3.8% sodium citrate. After centrifugation, plasma was used immediately for aPIT determination. At day 0 and then once daily, blood cells and platelets were counted on an EDTA-containing tube. Routine biochemistry tests including serum levels of glucose, bilirubin, liver function tests (aspartat-amino transferase, alanineamino transferase), creatinine, cholesterol, and triglycerides were performed at day 0 and day 8. No mention will be made of these results because no significant difference was observed between UFH and LMWH groups.
In an ancillary study, anti-Xa activity was measured for 25 patients in one single center (17 patients in group 2 and eight patients in group 3). For these Fraxiparinetreated patients, blood was drawn 4 hours after a subcutaneous injection of Fraxiparine every day for 10 consecutive days. Aliquots of plasma were frozen at -30°C for analysis of anti-Xa activity by use of an amidolytic assay (Stachrom-Heparine, Diagnostica Stago, Asnieres, France).2' The standard curve was prepared using the same batch of Fraxiparine as that administered to the patients. This curve (range, 0.2-1.0 AXa IC U/ml) was obtained by adding the reference batch (10 AXa IC UIml) to normal plasma. Dilution of patients' plasma was made with the same normal plasma when anti-Xa activity was above 1 unit.
Statistical Analysis
SAS software was used for analysis. Statistical analysis did not involve patients from Group 4 (n=7). Comparisons were made by ANOVA and Student's t test. ANOVA was performed by PROGLM procedure with a repeated option (time factor: day 0 versus day 8) and a grouping factor (group factor: group 1 versus group 2 versus group 3). The comparison after treatments was performed by the interaction group times time. On day 0, comparisons between groups were performed by ANOVA with a grouping factor (group 1 versus group 2 versus group 3).
Comparisons of proportions were done by Pearson X 2, likelihood ratioX 2, or two-tailed Fisher's exact tests.
Efficacy analysis was performed according to the protocol requirements, i.e., severity index between 15% and 55% (70 patients), and also on all the patients assessed whatever the obstruction was; range, 6-66% (85 patients).
Intention-to-treat analysis was performed on all enrolled patients (94 patients). The difference day 0 minus day 8 is accepted as zero for unassessed patients for quantitative criteria.
Number of patients per group used for statistical analysis is given in Table 1 .
Because of small differences between groups on pulmonary vascular obstruction and Arnesen's score, the power of tests is less than 0.30. The power is given near the probability value for Fisher's exact tests on major bleeding occurrences.
All results are given as mean±SEM.
Results

Patients
In all, 101 patients were enrolled. Before completion of the trial, enrollment in two Fraxiparine groups stopped because of a high incidence of major bleedings: five of 26 patients (19.2%) in group 3 and four of seven patients (57.1%) in group 4. Distribution of the included patients at day 0 was as follows: 33 patients in group 1, 35 patients in group 2, 26 patients in group 3, and seven patients in group 4. The restricted number of patients included in group 4 (n=7) did not allow statistical analysis to be performed, as previously mentioned.
General characteristics and distribution of patients in the four groups are shown in Table 2 .
The first three groups did not differ significantly except for prolonged bed rest of more than 8 days (Pearson x2, p=0.04).
Pulmonary Angiographic Assessment
Among the 101 patients enrolled in the trial, 70 could be analyzed per protocol (see Table 1 for reasons for exclusions).
At day 8±1, the distribution of the 70 patients analyzed was as follows: 21 patients in group 1, 31 patients in group 2, and 18 patients in group 3. The pulmonary vascular obstruction before therapy was not significantly different among the three treatment groups (ANOVA, p=0.66). After day 8±1, improvement of pulmonary vascular obstruction was statistically significant in each group (ANOVA,p=0.0001) but not statistically different among groups 1, 2, and 3 (ANOVA, p=0.64) (Table 3A) . Pulmonary vascular obstruction was improved in 67 patients (95.7%), unchanged in one patient in group 3, and increased in two in group 2 (Table 4A ). Six patients in group 4 were assessed at day 8±1: four showed an improvement of pulmonary vascular obstruction, and two were unchanged.
When all patients included with pulmonary vascular obstruction (range, 6-66%) available for analysis are considered (n=85), the results appear to be similar. At day 8 ± 1, improvement of pulmonary vascular obstruction, expressed in percentage, was statistically significant in each group (ANOVA, p=0.0001) but not statistically different between groups (ANOVA, p=0.76) (Tables 3B  and 4B ). In intention-to-treat analysis (94 patients), no statistical difference was observed among groups.
Venographic Assessment
Among the 101 patients enrolled in the trial, 49 could be analyzed per protocol (see Table 2 for reasons for exclusions). At day 8+1, the distribution of the 49 patients analyzed was as follows: 12 patients in group 1, 26 patients in group 2, and 11 patients in group 3. At day 0, severity scores were not significantly different among the three treatment groups (ANOVA, p=0.64). At day 8+1, there was a significant improvement in the severity scores for the three groups analyzed (n =49) (ANOVA, p=0.0001) but not statistically different between them (ANOVA, p=0.95) (Table 5A ). Severity scores improved in 39 patients (79.6%) and remained unchanged in six patients (group 1, one; group 2, five). Venographic extension of the initial thrombus was observed in four patients (one patient in group 1, two patients in group 2, and one patient in group 3). The three patients in group 4 showed an improvement of the severity score.
When all patients included with pulmonary vascular obstruction (range, 6-66%) available for analysis are considered, the results appear to be similar. At day 8±1, there was a significant improvement in the severity scores for the three groups analyzed (n=59 patients) (ANOVA, p=0.0001) but not statistically different between them (ANOVA, p=0.95) (Table SB) .
Clinical Recurrences of Thromboembolic Events
During the 14-day treatment period, no clinical recurrence occurred in groups 1, 2, and 3. In group 4, two patients developed clinical signs possibly related to recurrences of pulmonary embolism. In one patient, this was ruled out by a subsequent angiography. The second patient died from sudden cardiac arrest at day 3, but necropsy was not performed.
Death
During the study, three patients died while on therapy: one patient in group 1 from myocardial infarction 5 days after the start of treatment, one patient in group 2 10 7 5 1 0.50 Previous heart failure (n) 6 3 6 1 0.28 Cancer (n) 3 3
Bed rest (>8 days) (n) 9 10 14 3 0.04 PE context Surgical (n) 11 18 9 2 0.24 Medical (n) 22 17 17 5 PE, pulmonary embolism. Except bed rest (p=0.04), all other differences are not significant. *Except for group 4. tStatistical summary not performed. from septic shock on day 7, and one patient in group 4, already mentioned, from sudden cardiac arrest on day 3.
Hemorrhagic Complications
In the 101 patients included in the trial, major bleeding occurred in two of 33 patients (6%) in group 1: one retroperitoneal bleeding at day 7 and one thigh hematoma at day 1 requiring transfusion without sequelae. In group 3, hemorrhagic complications occurred in five of 26 patients (19.2%): two retroperitoneal bleedings at day 3 and day 13 (transfusion), one hematoma after venipuncture at day 9 (transfusion), one TABLE 3. Results of Angiographic Severity Score abdominal hematoma at day 14 (transfusion), and one pelvic hematoma at day 13 (no transfusion). All these patients presented no sequelae. In group 4, major bleeding occurred in four of seven patients (57.1%): one retroperitoneal bleeding at day 2 (the patient died from sudden cardiac arrest at day 3), one intraperitoneal bleeding at day 11 (transfused), one hematoma after venipuncture at day 12 (neurological sequelae), and one pelvic hematoma at day 10 (without sequelae). No major bleeding was observed in group 2 ( Table 6 ). The frequency of these hemorrhages in groups 3 and 4 led to the cessation of inclusion in these groups after the 26th A. Evolution of pulmonary vascular obstruction in the patients included according to the protocol's requirements, i.e., PE and the seventh patient, respectively. Comparison between groups 1, 2, and 3 showed no difference between groups 1 and 2 (Fisher's exact test, p=0.23, pow-er=0.11) and between Groups 1 and 3 (Fisher's exact test, p=0.22, power=0.20) on bleeding incidence, but there was a higher incidence of major bleedings in group 3 compared with group 2 (Fisher's exact test, p=0.01, power=0.55). Minor bleedings that resolved spontaneously were observed in 19 patients: seven patients in group 1 (21.2%), four patients in group 2 (11.4%), six patients in group 3 (23%), and two patients in group 4 (28.6%).
If we consider the 70 patients included according to the protocol's requirements (pulmonary embolism of 15-55%), no major bleeding was observed in group 1 (21 patients) and group 2 (31 patients); two of 18 patients (11.1%) in group 3 presented a major bleeding (retroperitoneal bleeding and pelvic hematoma). Minor bleedings that resolved spontaneously were observed in four patients: two of 21 in group 1 (hematuria), one of 31 in group 2 (epistaxis), and one of 18 in group 3 (epistaxis). No extensive hematomas at injection sites were found in the LMWH groups.
Early Cessation of Treatment
Treatment was prematurely interrupted in 16 patients: four in group 1, five in group 2, two in group 3, and five in group 4. The causes and evolutions are reported in Table 7 .
Hematology
A marked decrease in platelet count (<100,000/mm3) was observed in three patients: one in group 1 (350,000/ mm3 at day 0 to 83,000/mm3 at day 9 -i.e., a 76% decrease), one in group 2 (366,000/mm3 at day 0 to 28,000/mm3 at day 12-a 92% decrease), and one in group 4 (136,000/mm3 at day 0 to 30,000/mm3 at day 10 -a 78% decrease). An aggregation test for the presence of normal platelets in the patient's plasma with UFH or Fraxiparine was performed in two patients and was positive in one of them (group 1). None of these three patients developed clinical complications. Platelet counts spontaneously returned to normal after cessation of treatment.
Biological Activity aPTT ratio (patient/control) was analyzed during the 14 study days. Before treatment (day 0), ANOVA did not demonstrate any significant difference in the values between groups 1, 2, and 3: 1.16+0.09, 1.04±+0.04, and 1.11+0.07, respectively (ANOVA, p=0.36).
During the treatment, in group 1, mean aPTT values were uniformly elevated (range, 2.13-2.92) and significantly higher than those observed in the other two groups (ANOVA, p<0.0001). In groups 2 and 3, mean aPiT values varied between 0.99 and 1.11 (group 2) and between 1.09 and 1.22 (group 3) during the 14 days of treatment without significant time effect (ANOVA, p=0.49 andp=0.39, respectively). Comparison between these two groups did not show any statistically significant difference (ANOVA, p=0.69) (Figure 1 ).
Anti-Xa activity assay (IC U/ml) was performed in 17 patients in group 2 and eight patients in group 3. Anti-Xa activity on treatment was 2.44±0.19 (group 2) and 3.72+0.46 (group 3) (Student's t test, p=0.005). Mean anti-Xa plasma levels varied between 1.8 and 2.8 (group 2) and 2.5 and 4.5 (group 3) during the 10 days ( Figure 2 ). There was a significant rise in the anti-Xa activity between day 2 and day 7 for the two groups (paired Student's t test, p=0.0018). But between day 7 and day 10, these values remained stable. The anti-Xa activities in two patients (group 3) with acute major bleeding were 3.6 (day 5) and 7 AXa IC U/ml (day 10). aPTT ratios were 0.94 and 1.74, respectively.
Discussion
The main objective of this study was to determine the optimal dosage of Fraxiparine to use in the curative treatment of submassive PE. Fraxiparine was administered subcutaneously at a fixed daily dose of either 400, 600, or 900 AXa IC U/kg without laboratory control adjustments and compared with the reference treatment of submassive PE, i.e., continuous intravenous UFH with daily dose adjustments according to the results of aPTT. 3 Our results suggest that among the three Fraxiparine daily dose regimens tested, the 400-AXa IC U/kg dose regimen has the best efficacy/ tolerance ratio. Compared with this regimen, the 600-AXa IC U/kg dosage has a similar antithrombotic effect but carries a higher bleeding risk. In the 900-AXa IC U/kg group, the bleeding rate was so high that the patient enrollment was interrupted prematurely, precluding any assessment of the antithrombotic effect of this high-dose Fraxiparine regimen.
Compared with UFH, a daily dose of 400 AXa IC U/kg of Fraxiparine administered subcutaneously led to the same improvement in pulmonary vascular obstruction without increasing the PE recurrence or bleeding rates.
Even though this dose-finding study allowed us to find the optimal Fraxiparine dosage for the curative treatment of PE, the comparison between this treatment regimen and UFH should be interpreted cautiously, considering the limited number of patients. These results are in line with those of a previous large comparative study, however (166 patients) with a fixed daily dose (450 AXa IC U/kg) of Fraxiparine and UFH in the treatment of DVT.16 In that study, there is a better phlebographic improvement in the Fraxiparine group and similar low bleeding rates in the two groups (Fraxiparine, 2.3% versus UFH, 5%). Thus, the antithrombotic efficacy and the tolerance of a fixed 400-450-AXa IC U/kg dose of Fraxiparine administered subcutane- Other controlled studies13-15 have been performed with other LMWHs in the curative treatment of venous thromboembolism that exhibited similar efficacy/safety ratios, but a comparison with the present study is impaired by several major differences in the study design: different routes of administration, different compounds, early associated oral anticoagulants during the trial period, and dosage adjusted according to anti-Xa plasma levels. [13] [14] [15] A subcutaneous administration of LMWH at a fixed dose offers several advantages over the continuous intravenous infusion of UFH adjusted daily: a more comfortable pattern of treatment for the patient because of earlier mobilization, less nursing time, and less loading work for laboratories.
The anticoagulant action of standard heparin results primarily from its ability to accelerate the inhibition of various coagulation proteases, among them factor Xa and thrombin by antithrombin III. Unlike UFH, LMWH inhibits primarily factor Xa with a slight antithrombin effect and so increases anti-Xa-to-anti-IIa activity ratio.2223 It was then suggested that LMWH curative treatments should be monitored and adjusted in relation to anti-Xa activity.14 '5 In different experimental models of thrombosis, however, no clear relation was observed between anti-Xa activities and antithrombotic efficacy or bleeding potential.6 In our study, anti-Xa activity was assayed daily in 25 patients belonging to groups 2 and 3 during 10 treatment days. The mean anti-Xa activity in group 3 (in which the bleeding rate was high) was significantly higher than the one measured in group 2 (in which no bleeding was observed). Two of the 25 patients had severe bleeding and concomitant high anti-Xa activities of 3.6 and 7 AXa IC U/ml, respectively; levels >3.6 AXa IC U/ml were also observed in eight patients without bleeding.
In our 23 patients, there was no correlation between the mean anti-Xa activity and the relative angiographic improvement (Figure 3) . Finally, the efficacy and safety of the fixed dose of 400-450 AXa IC U/kg of Fraxiparine seem to be well documented by the small number of severe bleedings observed in the two Fraxiparine trials (0 of 35 patients in the present trial and two of 85 in the DVT trial)'6 and the small number of pulmonary embolic events (0 of 35 patients in the present trial and one of 85 in the DVT trial). Thus, in regard to safety In conclusion, in patients with submassive PE, Fraxiparine administered subcutaneously at a fixed daily dose of 400 AXa IC U/kg shows the best efficacy/safety ratio compared with the two higher dosages tested. The finding of comparable angiographic improvements, PE recurrence, and bleeding rates for intravenous UFH and the 400 Fraxiparine regimen requires confirmation of efficacy and safety in a larger comparative study versus UFH in patients with submassive PE. 
